FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2146203889> ?p ?o ?g. }

• W2146203889 endingPage "197" @default.
• W2146203889 startingPage "192" @default.
• W2146203889 abstract "Purpose The purpose of this study was to determine the efficacy and tolerability of carboplatin, pemetrexed, and bevacizumab in patients with advanced, nonsquamous non–small-cell lung cancer (NSCLC). Patients and Methods The charts of consecutive patients with stage IIIB/IV nonsquamous NSCLC were reviewed. All patients receiving at least 1 cycle of the 3-drug regimen (pemetrexed 500 mg/m2, carboplatin area under the curve of 5-6, bevacizumab 15 mg/kg intravenously), were included for assessment of response, safety, and toxicity. Results A total of 27 patients received this regimen between February 2008 and July 2009; 63% were women. Median follow-up was 6.3 months (range, 1.6-21.1 months). Median number of cycles was 6 (range, 1-6 cycles); 67% completed 6 cycles; 83% went on to receive maintenance bevacizumab/pemetrexed. Among those who received maintenance, the median number of cycles administered was 4.5 (range, 1-18 cycles). Response rate was 52%; stable disease was observed in another 40%. On the basis of Kaplan-Meier analysis, actuarial overall survival was 83% at 12 months; actuarial progression-free survival was 83% and 63% at 6 and 12 months, respectively. Clinical improvement was noted in 41% of the patients, with clinical stability in another 48%. Grade 2 and 3 toxicities from the regimen included anemia (11% and 15%), fatigue (37% and 7.4%), febrile neutropenia (7.4%; grade 3 only), thrombocytopenia (7.4% and 0), and thromboembolic disorders (3.7% and 3.7%). Bevacizumab-induced side effects (any grade) included headaches (22.2%), epistaxis (30%), hemoptysis (3.7%), and hypertension (11%). No grade 4 or 5 toxicities were seen. Conclusion Combination carboplatin/pemetrexed and bevacizumab followed by maintenance therapy with pemetrexed/bevacizumab is effective, with response rates > 50%, acceptable toxicity, and promising early survival in patients with advanced nonsquamous NSCLC." @default.
• W2146203889 created "2016-06-24" @default.
• W2146203889 creator A5010747807 @default.
• W2146203889 creator A5022384270 @default.
• W2146203889 creator A5075546843 @default.
• W2146203889 creator A5076119705 @default.
• W2146203889 creator A5076698606 @default.
• W2146203889 creator A5077401044 @default.
• W2146203889 creator A5090256464 @default.
• W2146203889 date "2010-05-01" @default.
• W2146203889 modified "2023-09-26" @default.
• W2146203889 title "Carboplatin/Pemetrexed/Bevacizumab in the Treatment of Patients With Advanced Non–Small-Cell Lung Cancer: A Single-Institution Experience" @default.
• W2146203889 cites W1910732341 @default.
• W2146203889 cites W1917502393 @default.
• W2146203889 cites W1935885922 @default.
• W2146203889 cites W1976565907 @default.
• W2146203889 cites W1996141967 @default.
• W2146203889 cites W2005312471 @default.
• W2146203889 cites W2020159902 @default.
• W2146203889 cites W2020830322 @default.
• W2146203889 cites W2032332769 @default.
• W2146203889 cites W2036475994 @default.
• W2146203889 cites W2037139573 @default.
• W2146203889 cites W2041971752 @default.
• W2146203889 cites W2053736534 @default.
• W2146203889 cites W2073979951 @default.
• W2146203889 cites W2077125884 @default.
• W2146203889 cites W2079419271 @default.
• W2146203889 cites W2099725888 @default.
• W2146203889 cites W2100377347 @default.
• W2146203889 cites W2100785570 @default.
• W2146203889 cites W2112621029 @default.
• W2146203889 cites W2115658330 @default.
• W2146203889 cites W2124997388 @default.
• W2146203889 cites W2127405377 @default.
• W2146203889 cites W2128746268 @default.
• W2146203889 cites W2131988196 @default.
• W2146203889 cites W2133274403 @default.
• W2146203889 cites W2134667653 @default.
• W2146203889 cites W2139248078 @default.
• W2146203889 cites W2139675556 @default.
• W2146203889 cites W2145653040 @default.
• W2146203889 cites W2145835533 @default.
• W2146203889 cites W2150358925 @default.
• W2146203889 cites W2159711942 @default.
• W2146203889 cites W2166399931 @default.
• W2146203889 cites W2168258970 @default.
• W2146203889 cites W2607182122 @default.
• W2146203889 cites W4239714259 @default.
• W2146203889 doi "https://doi.org/10.3816/clc.2010.n.025" @default.
• W2146203889 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20439196" @default.
• W2146203889 hasPublicationYear "2010" @default.
• W2146203889 type Work @default.
• W2146203889 sameAs 2146203889 @default.
• W2146203889 citedByCount "11" @default.
• W2146203889 countsByYear W21462038892012 @default.
• W2146203889 countsByYear W21462038892013 @default.
• W2146203889 countsByYear W21462038892016 @default.
• W2146203889 countsByYear W21462038892017 @default.
• W2146203889 countsByYear W21462038892018 @default.
• W2146203889 countsByYear W21462038892022 @default.
• W2146203889 crossrefType "journal-article" @default.
• W2146203889 hasAuthorship W2146203889A5010747807 @default.
• W2146203889 hasAuthorship W2146203889A5022384270 @default.
• W2146203889 hasAuthorship W2146203889A5075546843 @default.
• W2146203889 hasAuthorship W2146203889A5076119705 @default.
• W2146203889 hasAuthorship W2146203889A5076698606 @default.
• W2146203889 hasAuthorship W2146203889A5077401044 @default.
• W2146203889 hasAuthorship W2146203889A5090256464 @default.
• W2146203889 hasConcept C126322002 @default.
• W2146203889 hasConcept C141071460 @default.
• W2146203889 hasConcept C143998085 @default.
• W2146203889 hasConcept C197934379 @default.
• W2146203889 hasConcept C2776256026 @default.
• W2146203889 hasConcept C2776694085 @default.
• W2146203889 hasConcept C2777063308 @default.
• W2146203889 hasConcept C2777240266 @default.
• W2146203889 hasConcept C2777802072 @default.
• W2146203889 hasConcept C2778239845 @default.
• W2146203889 hasConcept C2778248108 @default.
• W2146203889 hasConcept C2778336483 @default.
• W2146203889 hasConcept C2778375690 @default.
• W2146203889 hasConcept C2778850193 @default.
• W2146203889 hasConcept C2781413609 @default.
• W2146203889 hasConcept C2781451048 @default.
• W2146203889 hasConcept C71924100 @default.
• W2146203889 hasConceptScore W2146203889C126322002 @default.
• W2146203889 hasConceptScore W2146203889C141071460 @default.
• W2146203889 hasConceptScore W2146203889C143998085 @default.
• W2146203889 hasConceptScore W2146203889C197934379 @default.
• W2146203889 hasConceptScore W2146203889C2776256026 @default.
• W2146203889 hasConceptScore W2146203889C2776694085 @default.
• W2146203889 hasConceptScore W2146203889C2777063308 @default.
• W2146203889 hasConceptScore W2146203889C2777240266 @default.
• W2146203889 hasConceptScore W2146203889C2777802072 @default.
• W2146203889 hasConceptScore W2146203889C2778239845 @default.
• W2146203889 hasConceptScore W2146203889C2778248108 @default.
• W2146203889 hasConceptScore W2146203889C2778336483 @default.

• next